Can PRISM BioLab and Talus Bio finally drug the undruggable with AI and PPI chemistry?
PRISM BioLab and Talus Bio aim to drug the undruggable with AI–PPI chemistry. Find out how this platform could transform transcription factor drug discovery.
Can Harbour BioMed’s deal with Bristol Myers Squibb redefine the future of multispecific antibodies?
Harbour BioMed has signed a global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multispecific antibodies. The deal could be worth over $1.1 billion across upfront payments, milestones, and royalties. It also signals growing interest in platforms capable of generating novel immunotherapies for complex diseases. The announcement is not […]
Enhertu plus pertuzumab receives FDA approval for 1st-line HER2-positive metastatic breast cancer: Is the new standard of care here?
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (trastuzumab deruxtecan), in combination with pertuzumab, has received U.S. Food and Drug Administration approval as a first-line treatment for patients with unresectable or metastatic HER2-positive breast cancer, based on results from the DESTINY-Breast09 Phase III trial. The approval marks the first new frontline treatment in over a decade […]
Is Avenzo’s AVZO-021 the next big player in HR+/HER2- metastatic breast cancer?
Avenzo shares Phase 1 data on CDK2 inhibitor AVZO-021 in HR+/HER2- breast cancer. Find out what it means for post-CDK4/6 resistance strategies in 2025.
Can Biohaven’s BHV-1510 avoid the safety pitfalls of existing Trop2 ADCs in solid tumors?
Biohaven Ltd. presented updated Phase 1 clinical data on BHV-1510, its next-generation Trop2-targeting antibody-drug conjugate, at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London. The results, derived from a heavily pretreated population with advanced or metastatic solid tumors, showed encouraging response rates across non-small cell lung cancer, endometrial cancer, and urothelial […]
Atossa pivots into rare disease with FDA nod for (Z)-Endoxifen in Duchenne muscular dystrophy
Atossa Therapeutics has received Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration for (Z)-Endoxifen in Duchenne muscular dystrophy (DMD), a strategic shift that positions the estrogen receptor modulator for possible use in pediatric neuromuscular disorders. If approved, the program could qualify for a transferable Priority Review Voucher, but the timeline and […]
Marengo’s Invikafusp alfa shows early promise in metastatic breast cancer with dual-immunotherapy and ADC combination
Marengo Therapeutics has presented early-stage results from its STARt-002 clinical trial evaluating invikafusp alfa (Invika), a novel T cell immunotherapy candidate, in combination with sacituzumab govitecan (TRODELVY), an antibody-drug conjugate developed by Gilead Sciences. The data, shared during a late-breaking presentation at the 2025 San Antonio Breast Cancer Symposium, highlight the safety, pharmacodynamic activity, and […]
Why are “retired proteins” the hottest new targets in cancer immunotherapy research?
Few ideas have captivated both the scientific imagination and biotech investment flows quite like the cancer vaccine. For decades, the industry narrative was full of hope—and disappointment. The graveyard of failed trials stretches from Dendreon’s Provenge to once-hyped peptide and dendritic cell platforms. For every announcement of an “immune breakthrough,” there seemed to be a […]
Can Actinium’s ATNM-400 radiotherapy reshape treatment for resistant breast cancer?
Actinium Pharmaceuticals, Inc. has presented new preclinical data for its alpha-particle radiotherapy candidate ATNM-400 at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting potent anti-tumor activity across hormone receptor–positive, triple-negative, and therapy-resistant breast cancer models. The findings suggest that ATNM-400 could become a differentiated treatment option for patients with tumors that have progressed after […]
Could NanOlogy’s targeted intratumoral cisplatin rewrite the outlook for DIPG in children?
NanOlogy, LLC, a Texas-based clinical-stage oncology company, has announced the launch of a drug development program focused on diffuse intrinsic pontine glioma, known as DIPG, a universally fatal pediatric brainstem tumor. The company is advancing Large Surface Area Microparticle Cisplatin, or LSAM-cisplatin, designed for stereotactic intratumoral administration in children. Investigational New Drug–enabling studies are underway, […]